Author's response to reviews

Title: Expression of Cyclooxygenase-2 and B-cell lymphoma-2 in cystitis glandularis and primary vesical adenocarcinoma

Authors:

Zhongxing Li (wxd0422@163.com)
Guangcheng Ge (315839923@qq.com)
Rui Feng (970286944@qq.com)
Dan Wu (chao8746@126.com)
Bin Shen (drxbju@gmail.com)
Xing Wang (707035180@qq.com)
Yan Cui (amyyicss@sina.com)
Junrong Li (452478970@qq.com)
Xiaobing Ju (doctorjxb73@njmu.edu.cn)

Version: 2 Date: 16 July 2013

Author's response to reviews: see over
15 July 2013
Mr Reymon Ampalaya
Editor-in-Chief
BMC Urology

Dear Mr Reymon Ampalaya:

Thank you for your email correspondence on 11 July 2013, in which you encouraged us to revise our manuscript (MS: 1288440221101870) entitled “Expression of Cyclooxygenase-2 and B-cell lymphoma-2 in cystitis glandularis and primary vesical adenocarcinoma”.

Below you will find point-by-point responses to the editorial request. We have also attached the revised manuscript, which contains changes to the document based on the editorial request (highlighted in red).

We would like to thank the editor for their valuable comments and recommendations that have greatly improved the quality of this paper. We hope our responses are satisfactory.

Sincerely,

Xiaobing Ju, Prof
Response to the editorial request on MS: 1288440221101870 submitted to BMC Urology by Zhongxing Li et al.

Specific editorial request

1. Abstract—The Abstract of the manuscript should not exceed 350 words and must be structured into separate sections: Background, the context and purpose of the study; Results, the main findings; Conclusions, brief summary and potential implications. Please minimize the use of abbreviations and do not cite references in the abstract.

Response: We have reworded the Abstract based on the editorial request.

2. Requesting ethics statement—Research involving human subjects (including human material or human data) that is reported in the manuscript must have been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate.

Response: We add “The study was approved by the Institutional Review Board of the Nanjing Medical University, Nanjing, China. At recruitment, written informed consent was obtained from all participants involved in this study” in the Methods section of the manuscript.

3. In particular please provide us with the following sections in your manuscript:
   -- Competing interests
   -- Authors' contributions
   ---Conclusion

Response: In response to editorial request, we add the following sections in our manuscript:

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
Zhongxing Li, Guangcheng Ge and Rui Feng carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. Dan Wu carried out the immunoassays. Bin Shen participated in the sequence alignment. Xing Wang participated in the design of the study and performed the statistical analysis. Yan Cui and Junrong Li conceived of the study and participated in its design and coordination and helped to draft the manuscript. Xiaobing Ju conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Conclusion
The overexpression of COX-2 and Bcl-2 in CG suggests that the CG, especially the intestinal type, may be a premalignant lesion or convert into tumor in the presence of carcinogens.